Straits Times Index
3,300.64 +7.95 (+0.24%) Nikkei
38,269.35 -4.70 (-0.01%) Hang Seng
18,175.07 +412.04 (+2.32%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,464.43 -2,630.45 (-4.38%) CMC Crypto 200
1,257.96 -81.10 (-6.06%)
Axonics Modulation Technologies, Inc. (0I3.MU)
| Previous close | 62.50 |
| Open | 62.50 |
| Bid | 62.00 x N/A |
| Ask | 62.50 x N/A |
| Day's range | 62.50 - 62.50 |
| 52-week range | 44.20 - 63.50 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireAxonics Reports First Quarter 2024 Financial Results
IRVINE, Calif., April 30, 2024--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024.
PR NewswireBoston Scientific Announces Results for First Quarter 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per share (EPS), compared to $300 million or $0.21 per share a year ago, and achieved adjusted3 EPS of $0.56 for
ZacksAll You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
